PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
Trial Parameters
Brief Summary
This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
Eligibility Criteria
Inclusion Criteria: 1. Patients must be ≥ 1 years of age 2. Patients must demonstrate expression of at least one of the following HLA alleles by HLA genotyping (conducted at CHOP) to be eligible: HLA-A\*24:02, HLA-A\*24:03, HLA-A\*24:04, HLA-A\*24:07, HLA-A\*24:124, HLA-A\*24:143, HLA-A\*24:17, HLA-A\*24:242, HLA-A\*24:305, HLA-A\*24:314, HLA-A\*24:33, HLA-A\*24:353, HLA-A\*24:41, HLA-A\*24:51, HLA-A\*24:63, HLA-A\*24:87, HLA-A\*24:92, HLA-A\*23:01, HLA-A\*23:17, HLA-A\*23:25, HLA-A\*23:39, 3. Disease Status A. Patients must have high-risk neuroblastoma according to COG risk classification at the time of study enrollment. Patients who were initially considered low- or intermediate-risk, but then reclassified as high-risk are also eligible. B. Patients must have a previously histologically confirmed diagnosis of neuroblastoma. C. Patients must have recurrent/progressive, refractory or persistent neuroblastoma. D. Patients must have neuroblastoma for which standard curative measures do n